Company / Revenue per Share
Corcept Therapeutics Incorporated Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$7.24
FY2025
5-year range
$2.63 / $7.24
FY2021-FY2025
Trend
+11.0%
vs FY2024
Sector context
#56 of 154
Health Care
What the data says
At $7.24, Corcept Therapeutics Incorporated's revenue per share ranks #56 of 154 in the Health Care sector. Revenue per Share has increased for 7 consecutive years, from $0.71 in FY2018 to $7.24 in FY2025.
Based on SEC 10-K filings.
7.24 in FY2025 with a 5-year CAGR of +27.0%.
Improved from $4.47 to $7.24 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +29.4%
- 5-Year CAGR
- +27.0%
- 10-Year CAGR
- -
Sector benchmark
#56 of 154 in Health CareTop 36% of 154This company $7.24 Sector average $10.35
▼
-30.0% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's revenue per share has grown for 7 consecutive years.
- In FY2025, revenue per share increased 11.0% year-over-year.
- Ranks #56 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.24 | +11.0% |
| FY2024 | $6.53 | +45.9% |
| FY2023 | $4.47 | +33.9% |
| FY2022 | $3.34 | +27.2% |
| FY2021 | $2.63 | +19.7% |
| FY2020 | $2.19 | +58.5% |
| FY2019 | $1.38 | +95.2% |
| FY2018 | $0.71 | -49.8% |
| FY2017 | $1.41 | +483.3% |
| FY2016 | $0.24 | -51.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026